385 related articles for article (PubMed ID: 18212283)
1. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
; Leizorovicz A; Becker F
Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
[TBL] [Abstract][Full Text] [Related]
2. Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study".
De Backer TL; Vander Stichele RH; Van Bortel LM
Circulation; 2008 Sep; 118(10):e151. PubMed ID: 18765384
[No Abstract] [Full Text] [Related]
3. Buflomedil in peripheral arterial disease: trials and tribulations.
Conte MS
Circulation; 2008 Feb; 117(6):717-9. PubMed ID: 18268159
[No Abstract] [Full Text] [Related]
4. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease.
Diehm C; Allenberg JR; Pittrow D; Mahn M; Tepohl G; Haberl RL; Darius H; Burghaus I; Trampisch HJ;
Circulation; 2009 Nov; 120(21):2053-61. PubMed ID: 19901192
[TBL] [Abstract][Full Text] [Related]
5. Bleeding increases the risk of ischemic events in patients with peripheral arterial disease.
van Hattum ES; Algra A; Lawson JA; Eikelboom BC; Moll FL; Tangelder MJ
Circulation; 2009 Oct; 120(16):1569-76. PubMed ID: 19805650
[TBL] [Abstract][Full Text] [Related]
6. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis.
Basili S; Raparelli V; Vestri A; Di Tanna GL; Violi F
Thromb Haemost; 2010 Apr; 103(4):766-73. PubMed ID: 20174763
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.
Zoungas S; McGrath BP; Branley P; Kerr PG; Muske C; Wolfe R; Atkins RC; Nicholls K; Fraenkel M; Hutchison BG; Walker R; McNeil JJ
J Am Coll Cardiol; 2006 Mar; 47(6):1108-16. PubMed ID: 16545638
[TBL] [Abstract][Full Text] [Related]
9. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.
Grossman PM; Mendelsohn F; Henry TD; Hermiller JB; Litt M; Saucedo JF; Weiss RJ; Kandzari DE; Kleiman N; Anderson RD; Gottlieb D; Karlsberg R; Snell J; Rocha-Singh K
Am Heart J; 2007 May; 153(5):874-80. PubMed ID: 17452167
[TBL] [Abstract][Full Text] [Related]
10. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
Nenci GG; Gresele P; Ferrari G; Santoro L; Gianese F;
Thromb Haemost; 2001 Nov; 86(5):1181-7. PubMed ID: 11816704
[TBL] [Abstract][Full Text] [Related]
11. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease.
Vainas T; Stassen FR; Schurink GW; Tordoir JH; Welten RJ; van den Akker LH; Kurvers HA; Bruggeman CA; Kitslaar PJ
Eur J Vasc Endovasc Surg; 2005 Apr; 29(4):403-11. PubMed ID: 15749042
[TBL] [Abstract][Full Text] [Related]
12. Double-blind placebo-controlled trial of buflomedil in intermittent claudication.
Fonseca V; Mikhailidis DP; Barradas MA; Jeremy JY; Gracey L; Dandona P
Int J Clin Pharmacol Res; 1988; 8(5):377-81. PubMed ID: 3229875
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Hiatt WR; Money SR; Brass EP
J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
[TBL] [Abstract][Full Text] [Related]
14. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
[TBL] [Abstract][Full Text] [Related]
15. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up.
Zaugg M; Bestmann L; Wacker J; Lucchinetti E; Boltres A; Schulz C; Hersberger M; Kälin G; Furrer L; Hofer C; Blumenthal S; Müller A; Zollinger A; Spahn DR; Borgeat A
Anesthesiology; 2007 Jul; 107(1):33-44. PubMed ID: 17585213
[TBL] [Abstract][Full Text] [Related]
16. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?
Boissel JP; Peyrieux JC; Destors JM
Thromb Haemost; 1989 Sep; 62(2):681-5. PubMed ID: 2683189
[TBL] [Abstract][Full Text] [Related]
17. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
[TBL] [Abstract][Full Text] [Related]
18. Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery.
; Devereaux PJ; Yang H; Guyatt GH; Leslie K; Villar JC; Monteri VM; Choi P; Giles JW; Yusuf S
Am Heart J; 2006 Aug; 152(2):223-30. PubMed ID: 16875901
[TBL] [Abstract][Full Text] [Related]
19. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
Brass EP; Anthony R; Cobb FR; Koda I; Jiao J; Hiatt WR
J Am Coll Cardiol; 2006 Dec; 48(12):2539-45. PubMed ID: 17174195
[TBL] [Abstract][Full Text] [Related]
20. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
Rajagopalan S; Mohler ER; Lederman RJ; Mendelsohn FO; Saucedo JF; Goldman CK; Blebea J; Macko J; Kessler PD; Rasmussen HS; Annex BH
Circulation; 2003 Oct; 108(16):1933-8. PubMed ID: 14504183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
